Danaher Co. (DHR) Expected to Post Quarterly Sales of $4.92 Billion

Wall Street brokerages forecast that Danaher Co. (NYSE:DHR) will report $4.92 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Danaher’s earnings. The highest sales estimate is $4.98 billion and the lowest is $4.77 billion. Danaher reported sales of $4.51 billion in the same quarter last year, which would suggest a positive year over year growth rate of 9.1%. The firm is scheduled to issue its next earnings report on Thursday, July 19th.

On average, analysts expect that Danaher will report full year sales of $19.91 billion for the current fiscal year, with estimates ranging from $19.69 billion to $20.03 billion. For the next financial year, analysts anticipate that the firm will post sales of $20.84 billion per share, with estimates ranging from $20.68 billion to $21.04 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Danaher.

Danaher (NYSE:DHR) last issued its earnings results on Thursday, April 19th. The conglomerate reported $0.99 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.05. Danaher had a return on equity of 11.39% and a net margin of 13.56%. The firm had revenue of $4.70 billion for the quarter, compared to analysts’ expectations of $4.54 billion. During the same quarter last year, the firm earned $0.85 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year.

Several research analysts have commented on the company. Credit Suisse Group reissued an “outperform” rating on shares of Danaher in a research report on Friday, March 9th. Cowen reissued a “buy” rating and issued a $110.00 price objective on shares of Danaher in a research report on Tuesday, January 30th. Stifel Nicolaus reissued a “buy” rating and issued a $114.00 price objective (up from $108.00) on shares of Danaher in a research report on Thursday, April 19th. Robert W. Baird reissued a “buy” rating and issued a $106.00 price objective on shares of Danaher in a research report on Friday, April 20th. Finally, Jefferies Group reissued a “buy” rating and issued a $117.00 price objective on shares of Danaher in a research report on Friday, April 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $105.56.

Danaher traded down $0.03, hitting $102.29, during mid-day trading on Friday, Marketbeat reports. The company had a trading volume of 1,310,092 shares, compared to its average volume of 2,411,799. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.59 and a quick ratio of 1.15. Danaher has a 1 year low of $78.97 and a 1 year high of $104.82. The firm has a market capitalization of $70.84 billion, a PE ratio of 25.38, a price-to-earnings-growth ratio of 1.90 and a beta of 1.03.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 27th. Stockholders of record on Friday, June 29th will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date of this dividend is Thursday, June 28th. Danaher’s payout ratio is 15.88%.

In other news, Director Walter G. Lohr sold 10,578 shares of Danaher stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $97.90, for a total transaction of $1,035,586.20. Following the sale, the director now directly owns 19,821 shares of the company’s stock, valued at $1,940,475.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Rainer Blair sold 3,981 shares of Danaher stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $100.05, for a total value of $398,299.05. Following the sale, the insider now directly owns 49,751 shares in the company, valued at $4,977,587.55. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 267,077 shares of company stock worth $27,022,784. Corporate insiders own 11.90% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. North American Management Corp increased its holdings in Danaher by 0.4% in the fourth quarter. North American Management Corp now owns 123,093 shares of the conglomerate’s stock valued at $11,426,000 after buying an additional 512 shares during the last quarter. Gulf International Bank UK Ltd increased its holdings in Danaher by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 197,012 shares of the conglomerate’s stock valued at $19,289,000 after buying an additional 520 shares during the last quarter. FTB Advisors Inc. increased its holdings in Danaher by 14.9% in the fourth quarter. FTB Advisors Inc. now owns 4,064 shares of the conglomerate’s stock valued at $386,000 after buying an additional 528 shares during the last quarter. D.A. Davidson & CO. increased its holdings in Danaher by 4.3% in the fourth quarter. D.A. Davidson & CO. now owns 13,374 shares of the conglomerate’s stock valued at $1,241,000 after buying an additional 548 shares during the last quarter. Finally, Ramsay Stattman Vela & Price Inc. increased its holdings in Danaher by 0.7% in the first quarter. Ramsay Stattman Vela & Price Inc. now owns 84,028 shares of the conglomerate’s stock valued at $8,227,000 after buying an additional 550 shares during the last quarter. 76.66% of the stock is currently owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply